Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Celleron Therapeutics Limited has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The portfolio involves a distinct examiner, OH, TAYLOR V, who is the busiest examiner with 1 pending action. Prosecution is active in a distinct art unit. This focused profile indicates that the company's current patent efforts are concentrated on a single matter. Practitioners should monitor the specific examiner's tendencies in the biotechnology sector to manage the pending action.
The presence of a pending office action indicates a streamlined prosecution environment. Because the portfolio is limited to a single distinct examiner and a single distinct art unit, there is no internal baseline for comparing examiner behavior or art unit efficiency within the company's own data. Success for Celleron Therapeutics Limited depends on navigating the specific requirements of OH, TAYLOR V. This concentration under a single point of review simplifies administrative tracking but increases the impact of any single procedural hurdle.
In the Biotechnology & Pharmaceuticals field, where examination can be highly technical, having a distinct art unit involved suggests a consistent application of subject matter standards. However, the reliance on a distinct examiner means that the company's patent trajectory is currently subject to a single perspective. Practitioners should focus on the historical allowance rates and common rejection types associated with the specific examiner to optimize their response strategy for the 1 pending office action.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OH, TAYLOR V | 1 | 81.2% | +15.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18283158 | VACCINE ADJUVANT | OH, TAYLOR V | 60d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18283158 | VACCINE ADJUVANT | OH, TAYLOR V | 60d overdue |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18283158 | VACCINE ADJUVANT | OH, TAYLOR V | 1625 | §103§112 | Final Rejection | 60d overdue | Pending | Sep 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial